Benefits of Using High-Functionality Excipients in a Continuous Manufacturing Process

April 10, 2019

As pharmaceutical companies move increasingly toward changing production methods from batch to continuous processing, there is a need to re-evaluate the types and formulations of the excipients used. Within a continuous process, conventional monofunctional excipients must be added through individual feeders, potentially creating multiple sources of variability. In contrast, a single high-functionality co-processed excipient requires only one feeder, thus enhancing product performance while minimizing variability. 

Spotlight

Outpatient Imaging Affiliates

OIA partners with healthcare providers such as health systems, academic medical centers, and radiology groups to develop, market and operate quality, patient friendly, service oriented outpatient imaging centers. OIA’s business model is to invest equity in each project alongside its local partners while providing development, management, marketing, billing and collection services to the joint venture.

OTHER WHITEPAPERS
news image

The Never-Normal Future of Manufacturing

whitePaper | September 24, 2022

Let’s just say what we’re all thinking: 2020 was rough. It threw pretty much every element of our lives into disarray, and we suddenly had to become experts at navigating a new way of working, schooling and socializing.

Read More
news image

Measuring the COVID Effect on Clinical Trials

whitePaper | June 27, 2022

As the world begins its transition into a postpandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects that COVID-19 has brought.

Read More
news image

Coronavirus (COVID-19) and Its Effect on Pharmaceutical Marketing and Sales

whitePaper | March 16, 2020

With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.

Read More
news image

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1

Read More
news image

New technology advances biopharma chromatography productivity

whitePaper | February 16, 2023

Monoclonal antibody drugs (mAbs) make up more than 50 percent of the biologics on the market today, as well as a significant number of new drugs in the development pipeline. The value and impact of these therapies has been dramatic.

Read More
news image

10 Tips on Selecting Cartridge Dust Collection Equipment for Tablet Presses

whitePaper | December 28, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical.

Read More

Spotlight

Outpatient Imaging Affiliates

OIA partners with healthcare providers such as health systems, academic medical centers, and radiology groups to develop, market and operate quality, patient friendly, service oriented outpatient imaging centers. OIA’s business model is to invest equity in each project alongside its local partners while providing development, management, marketing, billing and collection services to the joint venture.

Events